Fidaxomicin-Register

The Fidaxomicin Registry is a multicentre, retrospective study in Germany comparing the use of fidaxomicin vs. vancomycin in immunocompromised patients with recurrent/refractory Clostridioides difficile infection between the years 2013 and 2023. The aim is to analyse the clinical and health economic parameters and outcomes in a 90-day follow-up. The study center in Frankfurt participated in the trial, while overall responsibility for the project was hold by the University Hospital Cologne.

This study is supported by an unrestricted research grant from Tillotts Pharma GmbH (Germany).